Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
Robert L. Ferris(University of Pittsburgh), Lisa Licitra(University of Milan), Sophie Wildsmith(AstraZeneca (United Kingdom)), Makoto Tahara(National Cancer Center Hospital East), С. И. Кутукова(City Clinical Oncology Center), Jérôme Fayette(Université Claude Bernard Lyon 1), Lyubov Zholudeva, Jean Fan(Johns Hopkins University), Ricard Mesı́a(Institut d'Investigació Biomédica de Bellvitge), Javier Caballero-Daroqui(Hospital Universitari i Politècnic La Fe), Ihor Vynnychenko(Sumy State University), Nassim Morsli(Boehringer Ingelheim (France)), Jagdish Shetty(AstraZeneca (United States)), Mikhail Dvorkin(Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center"), Helen Mann(AstraZeneca (United Kingdom)), Bhumsuk Keam(Seoul National University Hospital), Robert I. Haddad(Broad Institute), Amaury Daste(Centre Hospitalier Universitaire de Bordeaux), Caroline Even(Institut Gustave Roussy), Paul M. Clément(Universitair Ziekenhuis Leuven), C. Lafond(Centre Jean Bernard), Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta)
Cited by 365
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k